[{"command":"settings","settings":{"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJxdyl0KhDAMRtEN1XZJ8mliDaQ1pD-z_YFhUPDxHi5v07pSkjqFP4H_WZgEixRkflmb-RaDIzvsXMpF0HWHU_ht6RDt7HGHdblquM-WyIdB4yNxVBubSjuZvnheN14","theme":"ebvptld","theme_token":null},"ajaxTrustedUrl":[],"user":{"uid":0,"permissionsHash":"4867837929d82f46a0b8d631cb1b853ab572e5989466da9ff30f538d13a4af8e"}},"merge":true},{"command":"add_css","data":[{"rel":"stylesheet","media":"all","href":"\/sites\/default\/files\/css\/css_zFE0GntIr5sJtoaw0onuR1rz-A25LT_DlBnsJ-mCx8I.css?delta=0\u0026language=en\u0026theme=ebvptld\u0026include=eJxFykEOgCAMBMAPITzJLLRKkwJNAd_vTa-T4fzYUkoGx-2werRB0LPAKTQmQbpEF3sssCWjh2_ORL4NGn-Ju9vOKrMyvTgpIzs"},{"rel":"stylesheet","media":"all","href":"\/sites\/default\/files\/css\/css_rp-nJs0EOjtUdAxu7hbmuIO3NIwEYbwhfB4JNT82dPg.css?delta=1\u0026language=en\u0026theme=ebvptld\u0026include=eJxFykEOgCAMBMAPITzJLLRKkwJNAd_vTa-T4fzYUkoGx-2werRB0LPAKTQmQbpEF3sssCWjh2_ORL4NGn-Ju9vOKrMyvTgpIzs"}]},{"command":"add_js","selector":"body","data":[{"src":"\/sites\/default\/files\/js\/js_fgI_F9T9iHdlscNdB1Tqblhfn81ETkj65lf7riv4k8o.js?scope=footer\u0026delta=0\u0026language=en\u0026theme=ebvptld\u0026include=eJxLzi9K1U8pKi1IzNFLyUzMyU_XS8xKrNBJTSorKMlJ0c_MK8tMLYdzyyuLM8sr0wE6xBUe"}]},{"command":"openDialog","selector":"#drupal-modal","settings":null,"data":"\n  \u003Cdiv id=\u0022p205\u0022 class=\u0022js-inview paragraph paragraph--type--modal-card paragraph--view-mode--teaser modal wysiwyg\u0022\u003E\n         \n  \u003Ch3\u003E\u003Cstrong\u003EPTLD-1 ST STUDY\u003Csup\u003E12\u003C\/sup\u003E\u003C\/strong\u003E\u003C\/h3\u003E\n\u003Cp\u003E\u003Cspan class=\u0022regular\u0022\u003E\u003Cstrong\u003ESequential treatment: rituximab \u0026gt; CHOP\u003C\/strong\u003E\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022regular\u0022\u003EIn a Phase 2 study of patients with CD20+ PTLD refractory to initial RIS, 90% (53\/59) achieved complete or partial response after four weekly doses of rituximab followed by four 21-day cycles of CHOP.\u003C\/span\u003E\u003C\/p\u003E\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\n\u003Cdiv class=\u0022flex\u0022\u003E\n\u003Cdiv class=\u0022study1Card\u0022\u003E\n\u003Ch4 class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022purple-light\u0022\u003E\u003Cstrong\u003ERESPONSE\u003C\/strong\u003E\u003C\/span\u003E\u003C\/h4\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003C?xml version=\u00221.0\u0022?\u003E\n\n\n\n\u003C\/div\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003EORR after sequential treatment\u003C\/strong\u003E\u0026nbsp;\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022smallish\u0022\u003E(95% CI, 79\u201396%; n=59)\u003C\/span\u003E\u003C\/p\u003E\n\u003Ch4 class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022purple-light\u0022\u003E\u003Cstrong\u003EVS\u003C\/strong\u003E\u003C\/span\u003E\u003C\/h4\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study1-60%25.png?itok=WoGvL4AC\u0022 width=\u0022400\u0022 height=\u0022400\u0022 alt=\u002260 %\u0022 loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003EORR after rituximab\u003C\/strong\u003E\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022smallish\u0022\u003E(95% CI, 48\u201371%; n=70)\u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n\u003Cdiv class=\u0022study1Card\u0022\u003E\n\u003Ch4 class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022purple-light\u0022\u003E\u003Cstrong\u003ESURVIVAL\u003C\/strong\u003E\u003C\/span\u003E\u003C\/h4\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u003Cstrong\u003E6.6 years\u003C\/strong\u003E\u0026nbsp;\u003Cbr\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003Emedian OS\u003C\/strong\u003E (ITT, N=70)\u003C\/span\u003E\u003C\/p\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study1-61%25.png?itok=xClzlpbp\u0022 width=\u0022400\u0022 height=\u0022400\u0022 alt=\u002261 %\u0022 loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study1-55%25.png?itok=ZUWKPgh-\u0022 width=\u0022400\u0022 height=\u0022400\u0022 alt=\u002255 %\u0022 loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EMedian follow-up 5.1 years. In the per protocol analysis (N=63), median OS was not reached; OS at 3 and 5 years was 65% and 57%, respectively.\u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n\u003Cdiv class=\u0022study1Card\u0022\u003E\n\u003Ch4 class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022purple-light\u0022\u003E\u003Cstrong\u003ETIME TO PROGRESSION\u003C\/strong\u003E\u003C\/span\u003E\u003C\/h4\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003E77.4 months\u003C\/strong\u003E\u0026nbsp;\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022smallish\u0022\u003Emedian TTP\u003C\/span\u003E\u003C\/p\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study1-69%25.png?itok=ikTQft1G\u0022 width=\u0022400\u0022 height=\u0022400\u0022 alt=\u002269 %\u0022 loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study1-66%25.png?itok=3fglq_sg\u0022 width=\u0022400\u0022 height=\u0022400\u0022 alt=\u002266 %\u0022 loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EMedian TTP per protocol (N=63) was not reached (\u0026gt;86.9 months)\u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n\u003Cdiv class=\u0022study1Card\u0022\u003E\n\u003Ch4 class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022purple-light\u0022\u003E\u003Cstrong\u003EMORTALITY\u003C\/strong\u003E\u003C\/span\u003E\u003C\/h4\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study1-10.6%25.png?itok=9Gu5luYy\u0022 width=\u0022400\u0022 height=\u0022400\u0022 alt=\u002210.6 %\u0022 loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022smallish\u0022\u003E(7\/66)\u000bCHOP-associated mortality\u003Cstrong\u003E\u0026nbsp;\u003C\/strong\u003E\u003C\/span\u003E\u003C\/p\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u0026nbsp;\u003C\/p\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003E5 out of 7 \u003C\/strong\u003ECHOP-related \u0003deaths (71%) occurred \u0026nbsp;in\u003Cstrong\u003E\u0026nbsp;non-responders\u0026nbsp;\u003C\/strong\u003Eto rituximab\u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\n\u003Cdiv class=\u0022row\u0022 style=\u0022margin:0 -1.2rem;\u0022\u003E\n\u003Cdiv class=\u0022col-md-12\u0022 style=\u0022padding:1.2rem;\u0022\u003E\n\u003Cp\u003E\u003Cbr\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003EStudy design\u003C\/strong\u003E\u003C\/span\u003E\u003C\/p\u003E\n\u003Cul\u003E\n\u003Cli data-list-item-id=\u0022e4b20c7613dd02084b21054146decb0c5\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EInternational, multicentre, open-label phase 2 trial\u0026nbsp;\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e0e832fb7f0ca5253f4a20a563d1a512e\u0022\u003E\u003Cspan class=\u0022small\u0022\u003E70 treatment-naive adult SOT recipients with CD20-positive PTLD unresponsive to RIS\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022eb282c856a30dea1e694ed60a407f2d3e\u0022\u003E\u003Cspan class=\u0022small\u0022\u003ETreatment regimen: four courses of rituximab once a week followed by 4 weeks without treatment and four cycles of CHOP every 3 weeks\u0026nbsp;\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e80434073f42704565ff19c87f25634a3\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EPrimary endpoint: treatment efficacy, assessed by response rates in patients who completed rituximab and CHOP per protocol, and response duration in those who completed all planned therapy and responded\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n\u003Cdiv class=\u0022col-md-12\u0022 style=\u0022padding:1.2rem;\u0022\u003E\n\u003Cp\u003E\u003Cbr\u003E\u003Cspan class=\u0022regular smallish\u0022\u003E\u003Cstrong\u003EAdverse events\u003C\/strong\u003E\u003C\/span\u003E\u003C\/p\u003E\n\u003Cul\u003E\n\u003Cli data-list-item-id=\u0022eedcee632bf219999215abab82341587f\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EGrade 3\/4 infections in 41% of patients\u0026nbsp;\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022ea53a9bc56f9e9d3d4f8a1a52ae4b641a\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EGrade 3\/4 leukopenia in 68% of patients\u0026nbsp;\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e49b1d65f323d192e4997d9c23fe6284f\u0022\u003E\u003Cspan class=\u0022small\u0022\u003E11% experienced CHOP-associated treatment-related mortality\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\n\n\n      \u003C\/div\u003E\n","dialogOptions":{"width":"60%","modal":true,"title":""}}]